A randomised controlled blinded trial to investigate the effect of hyoscine butylbromide during colonoscopy on rates of polyp detection.
In patients undergoing standard fibreoptic colonoscopy at a single centre, randomly allocated to receive hyoscine butylbromide or saline; a comparison of polyp detection rates between the two groups is to be undertaken to improve detection of colonic polyps.
Dr A Kaffes
300 participants
Dec 1, 2008
Interventional
Conditions
Summary
Some colonic polyps are not seen during colonoscopy, and new therapies are frequently tested to decrease the 'miss-rate' of around 15-20 %. The aim of this study is to test the hypothesis that using an antispasmodic drug (hyoscine butylbromide - also known as buscopan), given as a single intravenous dose during colonoscopy, that polyp detection rates may be improved. The study population will be all patients (who agree to participate)booked in for routine colonoscopy for any indication at a university hospital centre.
Eligibility
Inclusion Criteria2
- Booking for colonoscopy.
- Intact colon (no previous colonic resection).
Exclusion Criteria11
- Emergency colonoscopic procedure
- Previous colon resection
- Already included in this study
- Glaucoma
- Achalasia
- Previous urinary retention
- Known bowel obstructions
- Myasthenia gravis
- Porphyria
- Fructose intolerance
- Megacolon
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
During the isolated procedure of a single colonoscopy using the standard equipment, monitoring and sedation; the intervention (a single dose of hyoscine butylbromide 20 mg intravenously over approximately 10 seconds, also commercially known as buscopan) will be administered upon intubation of the caecum.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12608000600347